Janssen disappointed with second NICE no for Spravato
NICE has concerns with the evidence submitted but Janssen insists the nasal spray is a cost-effective use of NHS resources
Read More
Tag: esketamine
Janssen submits Spravato expansion in EU
The J&J division seeks to expand the use to adults with major depressive disorder who have current suicidal ideation with intent.
Read More
New data highlights value of Janssen’s Spravato
The approval of the drug is a new way of treating adults with TRD that is unlike other treatment options in psychiatry.
Read More
Janssen files nasal spray for depression
Janssen has submitted a marketing application to the European Medicines Agency (EMA) seeking approval of investigational nasal spray esketamine for the treatment of major depressive disorder.
Read More
Phase III success for Janssen’s esketamine in treatment-resistant depression
Janssen has presented data from pivotal Phase III clinical studies backing use of esketamine spray in treatment-resistant depression.
Read More
Second breakthrough badge for Janssen’s antidepressive
Janssen’s esketamine has picked up a breakthrough therapy designation in the US as a treatment for major depressive disorder with imminent risk for suicide, potentially speeding up development and review timelines.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
